Annexon (ANNX) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Annexon (ANNX) over the past year, gaining 223.1% versus a gain of 27.0%. Annexon is the larger company by market cap ($758.3 million vs $657.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | NVCT |
|---|---|---|
| Share price | $4.00 | $20.13 |
| Market cap | $758.32M | $657.12M |
| 1-day change | -0.25% | -0.79% |
| YTD return | -20.32% | +166.62% |
| 1-year return | +26.98% | +223.11% |
| 5-year return | -81.82% | — |
| EPS (TTM) | $-1.13 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $29.28 |
| 52-week low | $2.54 | $5.55 |
| Distance from 52-week high | -44.29% | -31.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +75.86% |
| Average volume | 3.11M | 215.43K |
| Shares outstanding | 189.58M | 32.64M |
| Employees | 92 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed ANNX by 196.1 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Healthcare · Biotechnology · 92 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Healthcare · Biotechnology · 16 employees
ANNX vs NVCT FAQ
Which is bigger, Annexon or Nuvectis Pharma?
Annexon (ANNX) is larger, with a market capitalization of $758.32M compared with $657.12M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, ANNX or NVCT?
NVCT returned +223.11% over the past 12 months, compared with +26.98% for ANNX (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.